Ublituximab is a medication being studied for its effects on autoimmune diseases. It is administered either through an injection into a vein (intravenous) or under the skin (subcutaneous). The study aims to understand how the body processes this medication and how it affects the immune system in patients with autoimmune conditions.

Myasthenia Gravis – Myasthenia Gravis is a chronic autoimmune disorder that affects the communication between nerves and muscles, leading to muscle weakness. It occurs when the immune system mistakenly attacks the connections between nerves and muscles, disrupting the transmission of nerve signals. This results in varying degrees of muscle weakness, which can worsen with activity and improve with rest. Commonly affected muscles include those controlling eye and eyelid movement, facial expression, and swallowing. The severity of symptoms can fluctuate, and they may become more pronounced during periods of physical exertion or stress.

Relapsing Multiple Sclerosis – Relapsing Multiple Sclerosis is a form of multiple sclerosis characterized by episodes of new or worsening symptoms, known as relapses, followed by periods of partial or complete recovery. It is an autoimmune disease where the immune system attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body. Symptoms can vary widely, including fatigue, numbness, vision problems, and difficulty with coordination and balance. The disease progresses with alternating periods of relapses and remissions, where symptoms may improve or disappear. Over time, relapses can lead to a gradual increase in disability.